Core Viewpoint - Jacobson Pharmaceutical's licensing agreement with Europharma will expire on November 30, 2025, leading to a new licensing agreement effective from December 1, 2025, to January 27, 2028, with a monthly fee of HKD 247,000 [1] Group 1 - The new licensing agreement was established on October 28, 2025, between Europharma and Europharma (Hong Kong) [1] - The monthly licensing fee under the new agreement is set at HKD 247,000 [1] - The duration of the new agreement spans from December 1, 2025, to January 27, 2028 [1]

Group 1 - The core point of the article is that Euroasia (01711) expects a significant reduction in net loss for the six months ending September 30, 2025, to no more than HKD 3 million, compared to HKD 11 million in 2024, primarily due to effective cost control measures implemented during this period [1]

Core Viewpoint - The company expects a significant reduction in net loss for the six months ending September 30, 2025, to not more than HKD 3 million, compared to a loss of HKD 11 million in 2024, primarily due to effective cost control measures implemented during this period [1]. Financial Performance - The anticipated net loss for the upcoming period is projected to be not more than HKD 3 million [1]. - In comparison, the net loss for the same period in 2024 was HKD 11 million, indicating a substantial improvement [1]. Cost Management - The improvement in financial performance is attributed to the company's effective cost control measures [1]. Future Reporting - The company has not yet finalized the unaudited interim results for the period and plans to publish these results in late November 2025 [1].

Core Viewpoint - The company, Euroasia (01711), expects a significant reduction in net loss for the six months ending September 30, 2025, to not more than HKD 3 million, compared to a loss of HKD 11 million in 2024, primarily due to effective cost control measures implemented during this period [1]. Financial Performance - The anticipated net loss for the upcoming period is projected to be not more than HKD 3 million [1]. - This represents a substantial improvement from the previous year's loss of HKD 11 million [1]. Cost Management - The reduction in net loss is attributed to the company's effective cost control measures [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號: 1711） 盈利預告 本公告乃由歐化國際有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則第13.09(2)(a)條及香港法例第571章證券及期貨 條例第XIVA部之內幕消息條文而作出。 本公司董事會（「董事會」）謹此知會本公司股東及潛在投資者，根據對本集團所得 最新財務資料進行之初步評估，本集團截至2025年9月30日止六個月（「本期間」）之 淨虧損預期將大幅收窄至不多於3,000,000港元（2024年：11,000,000港元），主要是由 於本集團於本期間實施了有效的成本控制措施。 由於本集團尚未落實本期間之未經審核中期業績（「中期業績」），本公告所載資料 僅根據現有所得資料而作出。中期業績擬定於 2025 年 11 月下旬刊發。 楊政龍 香港，2025年10月22日 於本公告日期，董事會成員為： 執行董事： 楊 ...

Core Viewpoint - The company has entered into a total leasing agreement with Emperor International and AY Industries, effective from October 1, 2025, to March 31, 2027, to regulate leasing transactions between the parties [1][2] Group 1: Leasing Agreement Details - The leasing agreement includes properties located in Hong Kong, such as office units and retail shops, with monthly rents ranging from HKD 28,500 to HKD 330,000 and property sizes from 856 square feet to 57,000 square feet [1] - The current leases with Emperor International and AY Industries have expiration dates between March 31, 2026, and December 31, 2026, with lease terms generally ranging from six months to three years [1] Group 2: Benefits of the Agreement - The total leasing agreement aims to streamline the reporting, announcement, and shareholder approval processes for new leases or renewals, thereby reducing administrative burdens and costs associated with compliance with listing rules [1] - The agreement is deemed fair and reasonable, aligning with the overall interests of the company and its shareholders [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號: 1711） 持續關連交易 2025 年總租賃協議 於 2025 年 10 月 16 日（交易時段後），本公司與英皇國際及 AY 產業控股訂立 2025 年總租 賃協議，以規管 (i) 本集團與英皇國際集團；及 (ii) 本集團與 AY 集團之間有關租賃交易 的安排，自 2025 年 10 月 1 日起至 2027 年 3 月 31 日止。 由於參考年度上限而計算之適用百分比率（定義見上市規則）少於 25%及總代價少於 10,000,000 港元，根據上市規則第十四 A 章，租賃交易須遵守公告、匯報及年度審閱之規 定，惟可獲豁免遵守股東批准之規定。 於 2025 年 10 月 16 日（交易時段後），本公司與英皇國際及 AY 產業控股訂立 2025 年總租 賃協議，以規管 (i) 本集團與英皇國際集團；及 (ii) 本集團與 AY 集團之間有關租賃交易 的安排， ...

Group 1 - As of October 8, 130 stocks reached their 52-week highs, with Mythical World Holdings (02949), Ouhua (01711), and Aisiji Group (08507) leading the increase rates at 61.90%, 57.55%, and 28.00% respectively [1] - The closing prices and peak prices for the top three stocks are as follows: Mythical World Holdings at 0.017 and 0.034, Ouhua at 0.184 and 0.219, and Aisiji Group at 0.640 [1] - Other notable stocks that reached new highs include Wanjia Group (00401) with a high rate of 26.09% and Xincheng Technology (00365) at 20.27% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Kangqiao Yuelife (02205) experiencing the largest decline at -48.11% [4] - Other stocks with significant declines include Yuxing Technology (08005) at -6.98% and Jingfa Property (01354) at -6.93% [4] - The lowest closing price recorded was for Kangqiao Yuelife at 0.465, with a lowest price of 0.275 [4]

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01711 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 800,000,000 | | 0 | | 800,000,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 800,000,000 | | 0 | | 800,000,000 | 第 2 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 歐化國際有限公司 | | | 呈交日期: | 2025年10月6日 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 歐化國際有限公司 | | | 呈交日期: | 2025年9月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01711 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 800,000,000 | | 0 | | 800,000,000 | | 增加 / 減少 (-) | | | 0 | | 0 | ...